Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 23 October 2015 | By Zachary Brennan
In advance of a hearing next Thursday, the House Energy & Commerce Committee has released a draft discussion bill that would set up new regulations for in vitro clinical tests.
The 185-page draft bill lays out how it would create a new Center for In Vitro Clinical Tests within the US Food and Drug Administration (FDA). And although the bill refers to the tests as "in vitro clinical tests," it remains to be seen how FDA would regulate the tests differently from in vitro diagnostics (IVDs).
IVDs are tests FDA currently defines as being able to detect diseases, medical conditions or infections and are typically developed by laboratories and IVD companies for use in hospitals and other clinical settings, but can also be developed and marketed directly to consumers.
The bill also comes as FDA in August announced plans via a draft guidance to regulate lab-developed tests more similarly to the way it regulates IVDs. That guidance, if finalized, could place a new burden on industry and academic hospitals that develop such tests.
However, this latest draft bill, which if enacted would presumably work in tandem with the FDA guidance, also notes that these regulations will exclude any test intended by its developer to be for nonclinical uses, such as for forensic testing, drugs-of-abuse testing for employment, insurance and genetic testing for nonclinical purposes.
Classification System
According to the draft bill, the FDA center (similar to what the FDA draft guidance for lab-developed tests unveiled) will be tasked with classifying in vitro clinical tests as high-risk (if an inaccurate test result would cause serious harm, or death, to the patient), moderate-risk (if an inaccurate result for the intended use would cause non-life-threatening injury) and low-risk (meaning an inaccurate result would cause minimal or no harm, immediately reversible harm, or no patient disability).
If an in vitro clinical test has multiple intended uses, then the test will be classified based on the intended use of the highest-risk class, according to the draft.
And not later than 90 calendar days after the date of enactment of the bill, FDA would be expected to establish advisory panels to review and consider the classification of each in vitro clinical test. The bill notes that panel members are expected to include physicians, consumers and the in vitro clinical test manufacturing and laboratory industries.
But all classifications made by FDA and the advisory panels can be appealed by industry.
Premarket Approvals
For moderate- and high-risk in vitro clinical tests, the new FDA center will also be tasked with determining whether a test is analytically valid and clinically valid for its intended use based on applications submitted by the manufacturer before it hits the market.
But for the moderate-risk devices, FDA’s burden will be lessened as it will be able to establish by regulation a process under which third parties may review and approve the devices.
There will also be expedited, alternative review pathways by which a manufacturer can submit for approval a test meant for rare diseases, unmet needs or emergency use.
And for low-risk devices, FDA will approve them “so long as the developer of the test submits a notification regarding the test.”
Other Provisions
The draft also includes details on premarket requirements for modifications to in vitro clinical tests, the registration of such tests, and other information on the investigational and research use of in vitro clinical tests.
Adverse event reporting requirements and more information on the way industry can appeal a particular classification are also included in the draft.
Text of the Discussion Draft
Notice of the Hearing
Tags: LDTs, lab-developed tests, IVDs, in vitro diagnostics, in vitro clinical tests, diagnostics
Regulatory Focus newsletters
All the biggest regulatory news and happenings.